Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC)

 Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC)

Leo Pharma Collaborates with PellePharm for the Development of Drug Candidate for Gorlin Syndrome and Basal Cell Carcinoma (BCC)

Shots:

  • Leo Pharma to invest $70M as equity investment in Pelle with R&D support to initiate P-III trial for Patidegib globally. Leo Pharma has an option to acquire Pelle, in all stock transaction
  • If Leo exercises its option Pelle to receive $690M as total deal value with milestones and royalties on sales. The P-III trial for Patidegib is expected to initiate in Q1’19
  • Patidegib is a topical gel, received FDA’s Breakthrough Therapy & Orphan Drug Designation, for the treatment of Gorlin Syndrome

Click here to read full press release/ article | Ref: Leo Pharma | Image: Business Wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post